This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position | The Motley Fool
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

Source: The Motley Fool
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.